DiscoveRx Corporation & Jubilant BioSys Ltd. Announce Co-Marketing Agreement for Screening Services
BANGALORE, India, January 11 /PRNewswire-FirstCall/ -- Jubilant Biosys Limited, based in Bangalore, an integrated Drug Discovery and Development solution provider, a subsidiary of Jubilant Organosys Ltd, headquartered in Noida, announced today that it has entered into a co-marketing agreement to provide screening solutions, with DiscoveRx Corporation (Fermont, USA), a premier provider of innovative cell based assay solutions for GPCR, Kinases, NHR and Proteases.
This agreement allows Jubilant access to DiscoveRx PathHunter(TM) and cAMPHunter(TM) cell lines and proprietary EFC chemiluminescent detection technology to perform screening on behalf of Jubilant's customers. The agreement also enables DiscoveRx to expand its platform technology to offer screening solutions from India.
DiscoveRx's PathHunter(TM) ss-Arrestin and HitHunter(TM) cAMP assays are homogeneous chemiluminescent assays which are rapidly becoming GPCR screening platform of choice for screening and profiling applications. Jubilant's demonstrated capabilities in discovery research state of the art medicinal chemistry, modeling, structural biology and screening facilities including High Throughput screening facility supported by automated compound management and visualization tools coupled with the DiscoveRx award winning assay platform offers global pharmaceutical companies access to cost effective screening and lead generation services that will enable and accelerate global drug discovery efforts.
Commenting on the Collaboration, Dr. Kailash Swarna, COO, Global Drug Discovery, at Jubilant Biosys said:
"We are pleased to announce this agreement with DiscoveRx, and look forward to the prospect of providing value to our customers using DiscoveRx PathHunter(TM) and HitHunter(TM) technologies. This partnership continues to demonstrate Jubilant's mission to partner with leading technology providers that provide access to cutting edge and innovative solutions to accelerate global drug discovery efforts with our collaborators."
Pyare Khanna, President and CEO, DiscoveRx Corporation says,
"DiscoveRx constantly strives to provide our truly innovative solutions to screening community. We are determined to help expedite the drug discovery processes and are delighted with this relationship with Jubilant. Our customers require an easy access to our innovative product portfolio and such partnerships will add value to our efforts of bringing industry leading portfolio of PathHunter(TM) and HitHunter(TM) GPCR assays to a broader audience."
About DiscoveRx Corporation
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of B-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. The Company is also a recipient of two Frost and Sullivan 2008 awards: Award for Innovation in North American Healthcare Market as well as a European Product Line Strategy Award for it's GPCR Cell Based assay portfolio. For more information on DiscoveRx products, please visit http://www.discoverx.com.
About Jubilant Biosys:
Jubilant Biosys Ltd., a subsidiary of Jubilant Organsys Ltd., provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 450 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharmacy chem., molecular modeling, crystallography and information technology supporting discovery efforts. For more information please visit: http://www.jubilantbiosys.com
CONTACT: Contacts: DiscoveRx Corporation, Sailaja Kuchibhatla, Sr. VP
Business Development, DiscoveRx Corp. skuchibhatla@discoverx.com;
+1-510-979-1415 ext. 104, Jubilant Biosys Ltd. Esha Kakkar, Executive -
Corporate Planning, Jubilant Biosys Ltd. Ph: +91-80-66628683,
esha_kakkar@jubilantbiosys.com